Ed Nash comment from his report following the presentation "If positive efficacy signals from TH1902 can be demonstrated in the basket trial, we
believe it will be an important stock-moving event. We currently do not include the
company’s oncology program in our model but will do so once clinical proof of concept
is established; therefore, this program represents potential upside to our current
projections."